Abstract
Pediatric migraine is a disabling condition, which can cause a significant impact on quality of life. Currently, no drugs have been approved by the FDA for its preventive treatment. Our aim was to review the medical literature concerning the efficacy and tolerability of topiramate in the prophylactic treatment of migraine in children and adolescents. A total of five papers were reviewed: two randomized controlled trials (RCTs), a post-hoc subset analysis of adolescents who had been included in three RCTs carried out on adults and two open studies. Topiramate has been proven to reduce headache frequency and the accompanying disability. The frequency of side effects varied considerably among studies, the most frequent being weight loss, anorexia, abdominal pain, difficulties in concentrating, sedation and paresthesia. Since these adverse events, although often transitory, may be distressing for the child, we strongly recommend to assess the disability caused by the migraine episodes before deciding to initiate a prophylactic treatment. Nevertheless, dropout rates due to side effects in the studies were very low.
Keywords: Migraine, Headache, Children, Pediatric, Topiramate
Full Text
The Full Text of this article is available as a PDF (144.5 KB).
Acknowledgments
Conflict of interest
None.
Contributor Information
Diana Ferraro, Email: perdiana@tin.it.
Girolamo Di Trapani, Phone: +39-6-30154435, FAX: +39-6-35501909, Email: gditrapani@rm.unicatt.it.
References
- 1.Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. Br Med J. 1994;309:765–769. doi: 10.1136/bmj.309.6957.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache. 1994;34:319–328. doi: 10.1111/j.1526-4610.1994.hed3406319.x. [DOI] [PubMed] [Google Scholar]
- 3.Stewart WF, Linet MS, Celentano DD, Natta M, Ziegler D. Age and sex-specific incidence rates of migraine with and without aura. Am J Epidemiol. 1991;134:1111–1120. doi: 10.1093/oxfordjournals.aje.a116014. [DOI] [PubMed] [Google Scholar]
- 4.Hershey AD, Winner PK. Pediatric migraine: recognition and treatment. J Am Osteopath Assoc. 2005;105(4 Suppl. 2):2S–8S. [PubMed] [Google Scholar]
- 5.Lewis DW, Scott D, Rendin V. Treatment of pediatric headache. Expert Opin Pharmacother. 2002;3:1433–1442. doi: 10.1517/14656566.3.10.1433. [DOI] [PubMed] [Google Scholar]
- 6.Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19:107–114. doi: 10.1046/j.1468-2982.1999.019002107.x. [DOI] [PubMed] [Google Scholar]
- 7.Hershey AD, Powers SW, Vockell ALB, LeCates SL, Kabbouche MA, Maynard MK. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology. 2001;57:2034–2039. doi: 10.1212/wnl.57.11.2034. [DOI] [PubMed] [Google Scholar]
- 8.Hershey AD, Powers SW, Vockell ALB, LeCates SL, Segers A, Kabbouche MA. Development of a patient-based grading scale for PedMIDAS. Cephalalgia. 2004;24:844–849. doi: 10.1111/j.1468-2982.2004.00757.x. [DOI] [PubMed] [Google Scholar]
- 9.Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, American Academy of Neurology Quality Standards Subcommittee. Practice Committee of the Child Neurology Society Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;28(63):2215–2224. doi: 10.1212/01.wnl.0000147332.41993.90. [DOI] [PubMed] [Google Scholar]
- 10.Lakshmi CV, Singhi P, Malhi P, Ray MJ. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. Child Neurol. 2007;22(7):829–835. doi: 10.1177/0883073807304201. [DOI] [PubMed] [Google Scholar]
- 11.Classification Committee for the International Headache Society The International classification of headache disorders. Cephalalgia. 2004;24:1–160. [Google Scholar]
- 12.Winner P, Pearlmann EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:1304–1312. doi: 10.1111/j.1526-4610.2005.00262.x. [DOI] [PubMed] [Google Scholar]
- 13.Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti W, Nye JS. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache. 2006;46:1503–1510. doi: 10.1111/j.1526-4610.2006.00610.x. [DOI] [PubMed] [Google Scholar]
- 14.Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche M. Effectiveness of topiramate in the prevention of childhood headaches. Headache. 2002;42:810–818. doi: 10.1046/j.1526-4610.2002.02185.x. [DOI] [PubMed] [Google Scholar]
- 15.Campistol J, Campos J, Casas C, Herranz JL. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol. 2005;20:251–253. [PubMed] [Google Scholar]
- 16.Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx. 2006;3(2):181–191. doi: 10.1016/j.nurx.2006.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]